Woodworth B A, Scribner J D, Scribner N K
Cancer Lett. 1986 Jun;31(3):293-7. doi: 10.1016/0304-3835(86)90150-3.
Using a two-step carcinogenesis protocol, SENCAR mice were initiated with 25 micrograms 7,12-dimethylbenz[a] anthracene (DMBA) and were then treated twice weekly with either (a) 0.5 mg beta-propiolactone (BPL) or (b) 1 microgram fluocinolone acetonide (FA) followed in 30 min by 0.5 mg BPL. The tumor incidence for the group receiving FA prior to BPL was significantly greater than for BPL alone (P less than 0.0005). Under these experimental conditions, BPL alone showed neither promoting activity nor complete carcinogenic activity. These results were not anticipated, but the reasons for their occurrence are being explored.
采用两步致癌方案，用25微克7,12 - 二甲基苯并[a]蒽（DMBA）启动SENCAR小鼠，然后每周两次用以下两种方式处理：（a）0.5毫克β-丙内酯（BPL）或（b）1微克醋酸氟轻松（FA），30分钟后再用0.5毫克BPL。在BPL之前接受FA的组的肿瘤发生率显著高于单独使用BPL的组（P小于0.0005）。在这些实验条件下，单独的BPL既没有促进活性也没有完全致癌活性。这些结果出乎意料，但正在探究其发生的原因。
